Open company graph database — free web & API
Login

SanBio Inc.

サンバイオ株式会社SanBio CompanyLimitedAlias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
33
Related companies
11
§01

Basic information

BASIC
Head office
13F, St. Luke's Tower, 8-1 Akashicho, Chuo-ku, Tokyo 104-0044, Japan
Chief executive
Keita Mori
Capital
8,375,000,000  (83 100 million)
Employees (non-consolidated)
29 people
Employees (consolidated)
33 people
Start date
2013-02-01
End date
§02

Websites

2 DOMAINS
§03

Business

1
Development, manufacturing, and sales of cell therapy drugs
§04

Related companies

11 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
SANBIO ASIA PTE. LTD.
Group Subsidiary
SanBio, Inc.
Group Subsidiary
NeurologyLive
Group
Investment Bridge Inc.
Customer
Shared Research Latitude Inc.
Customer
Yokohama TLO Inc.
Supplier
OCUMENSION (HONG KONG) LIMITED
Alliance
RX Japan
Alliance
General Incorporated Association "LINK-J"
Alliance
Sumitomo Dainippon Pharma Co., Ltd.
Alliance
Teijin Inc.
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

44 EVENTS

Established SanBio, Inc. in California, USASources

Received transfer of intellectual property related to the basic seeds that are the core technology of current development products from Yokohama TLO Corporation.Sources

SB623 Obtained manufacturing and sales approval for regenerative medicine products domestically.Sources

SB623 Designated as a target item for the FDA's RMAT in the field of chronic traumatic brain injury.Sources

Signed exclusive license agreement with Teijin Limited for SB623 in Japan for strokeSources

Obtained IND (Investigational New Drug) approval from the US FDA for SB623 for strokeSources

Signed option agreement with Daiichi Sankyo Company, Limited for SB623 in the US and Canada for strokeSources

Initiated Phase 1/2a clinical trial of SB623 for chronic stroke in the USSources

Dissolution of joint development and license agreement with Sumitomo Dainippon Pharma Co., Ltd. for the use of SB623 in chronic stroke in the United States and Canada.Sources

Established Japanese subsidiary SanBio CorporationSources

Obtained IND approval from the US FDA for SB623 for traumatic brain injurySources

Completed patient dosing in Phase 1/2a clinical trial of SB623 for stroke in the US. Moved headquarters of SanBio Inc. to Minato-ku, TokyoSources

Completed administration to patients in the United States for Phase 1/2a clinical trials of SB623 for stroke.Sources

Sankyo Co., Ltd. relocated its head office to Minato-ku, Tokyo.Sources

Carried out corporate restructuring with parent company in JapanSources

Reported results of Phase 1/2a clinical trial of SB623 for stroke at the International Stroke Conference 2014 in San Diego, USA (Professor Gary Steinberg, Chief of Neurosurgery at Stanford University, clinical trial director)Sources

Received approval from the US FDA for completion of Phase 1/2a and initiation of Phase 2b for SB623 in chronic strokeSources

Signed joint development and licensing agreement with Daiichi Sankyo Company, Limited for SB623 in the US and Canada for chronic strokeSources

Relocated headquarters of SanBio Inc. to Akashicho, Chuo-ku, TokyoSources

Listed on the Mothers Market of the Tokyo Stock Exchange (Securities code: 4592)Sources

Started full-scale development of SB623 for traumatic brain injury in JapanSources

Initiated Phase 2 clinical trial of SB623 for traumatic brain injury in the USSources

Initiated Phase 2b clinical trial of SB623 for chronic stroke in the USSources

Enrolled the first patient in the US for Phase 2b clinical trial of SB623 for chronic strokeSources

In the field of traumatic brain injury, the Pharmaceuticals and Medical Devices Agency (PMDA) accepts clinical trial notification for a Japan-U.S. global clinical trial (Phase 2).Sources

Enrollment of the first subjects in the United States for a Phase 2 clinical trial in the field of traumatic brain injury (SB623).Sources

Enrollment of the first subjects in Japan for a Phase 2 clinical trial in the field of traumatic brain injury (SB623).Sources

Established Usonian Investments LLC in 2017, with the CEO and CIO.Sources

Received a total of 20 million dollars in grants from the California Institute for Regenerative Medicine (CIRM) for a Phase 2b clinical trial for stroke.Sources

Completion of patient enrollment in the United States for a Phase 2b clinical trial of SB623 for chronic stroke.Sources

Agreement to terminate the exclusive license agreement with Teijin Limited for the use of SB623 in Japan for chronic stroke.Sources

Completion of patient enrollment in Japan and the United States for a Phase 2 clinical trial of SB623 for chronic traumatic brain injury.Sources

Designated as aSources

SB623 Designated as a pioneering review system target item as a regenerative medicine product by the Ministry of Health, Labour and WelfareSources

SB623 Designated as an advanced medical drug by the European Medicines Agency (EMA).Sources

Obtained aSources

Designated as aSources

Designated as aSources

Entered into a business alliance agreement with OCUMENSION (HONG KONG) LIMITED for research, development, and commercialization of regenerative cell drugs for retinal diseases in Greater China.Sources

Designated by the Minister of Health, Labour and Welfare as aSources

Established SANBIO ASIA PTE. LTD. in Singapore as the first subsidiary in Asia.Sources

Completed theSources

Moved to the Tokyo Stock Exchange Growth Market.Sources

Obtained aSources

§07

News

2 ARTICLES

Representative Mori to speak at Regenerative Medicine EXPOSources

Representative Mori of Sunbio Inc. announced that he will speak at the Regenerative Medicine EXPO hosted by RX Japan on May 21, 2026.

Sunbio Representative Mori to Speak at Regenerative Medicine ExpoSources

Representative Mori of Sunbio Inc. will speak at the Regenerative Medicine Expo held on May 21, 2026.

§08

Public records

GOV
National Tax Agency basic information6010601044067
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
サンバイオ株式会社
Trade name (kana)
サンバイオ
Name in English
Corporation type
301
Address
〒104-0044 東京都中央区明石町8番1号
Postal code
1040044
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-07-23
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2064149
METI gBizINFO6010601044067
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6010601044067
Trade name
サンバイオ株式会社
Trade name (kana)
サンバイオ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区明石町8番1号
Postal code
1040044
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
明石町8番1号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  森 敬太
Capital
8375431000
Employees
33
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-07-23
Key information
6010601044067
§09

Sources & updates

SOURCES
↑